Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity. The trailing-twelve-month return on equity at Akorn AKRX is 20.78%. Akorn's revenue for the same period is $304.28 million. The trailing-twelve-month return on equity at Salix Pharmaceuticals SLXP is 17.90%. Salix Pharma's operating margin for the same period is 26.47%. The trailing-twelve-month return on equity at Mylan MYL is 17.73%. Mylan's EPS for the same period is $1.52. The trailing-twelve-month return on equity at Sagent Pharmaceuticals SGNT is 16.09%. Sagent Pharma's profit margin for the same period is 12.09%.